Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr 15;203(8):1073-81.
doi: 10.1093/infdis/jiq161.

Effect of preexisting immunity to adenovirus on transgene product-specific genital T cell responses on vaccination of mice with a homologous vector

Affiliations

Effect of preexisting immunity to adenovirus on transgene product-specific genital T cell responses on vaccination of mice with a homologous vector

Larissa Herkenhoff Haut et al. J Infect Dis. .

Abstract

We evaluated changes in global and human immunodeficiency virus (HIV)-specific genital T cells after vaccination of female mice with a replication-defective adenovirus vector of human serotype 5 (AdHu5) expressing Gag protein of HIV-1, in the presence or absence of preexisting immunity to the vaccine carrier. Our data show that preexisting immunity causes a rapid and transient decrease of genital CD4(+) T cells without increasing the expression of chemokine (C-C motif) receptor 5. Furthermore, preexposure to AdHu5 affects long-term alterations in the magnitude and quality of vaccine-induced Gag-specific CD8(+) T cell responses. AdHu5-specific antibodies interfere with the induction of transgene product-specific CD8(+) T cell responses in systemic compartments, whereas some mechanism other than antibodies also seems to affect those that home to the genital tract.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Frequencies and numbers of genital CD4+ and CD8+ T cells. Graphs show percentages of CD4+ (A) and CD8+ (B) T cells, as well as absolute numbers of CD4+ (C) and CD8+ (D) T cells within the genital tract at different intervals after vaccination with AdHu5gag. Graphs show average frequencies or cell counts ± standard deviations (SD) for animals preexposed to adenovirus vector of human serotype 5 (AdHu5) and vaccinated with AdHu5gag 3 weeks later (i.m./i.m.; circles), mice vaccinated with the AdHu5gag vector without preexposure (-/i.m.; closed squares), and naive mice (open squares). Cells were isolated from the female genital tract and stained with a live cell stain and antibodies to CD4 and CD8. Statistical analyses compared 2 individual experiments, using 2-way analysis of variance followed by Bonferroni test. A, Both vaccinated groups had significantly lower frequencies of CD4+ cells over time than did the naive control group (P < .01). Frequencies of CD4+ cells for the 2 vaccinated groups differed only at week 8 after vaccination (P < .05). B, Frequencies of CD8+ cells were reduced in the 2 vaccinated groups early after vaccination (P < .01). Frequencies of CD8+ T cells in the nonpreexposed group were increased between weeks 1 and 8, compared with the naive group (P < .01). C, CD4+ cell counts were significantly different on days 3 and 7 between either of the vaccinated groups and the control group (P < .05 by t test). D, Cell counts were significantly different for CD8+ T cells only at week 1 when the 2 vaccinated groups were compared with the naive group (P < .05).
Figure 2.
Figure 2.
Phenotypes of genital CD4+ and CD8+ T cells. A, Phenotypes of CD4+ cells. B, Phenotypes of CD8+ cells. Cells from 5 mice were isolated at different time points, pooled, and stained with a live cell stain and antibodies to CD4, CD8a, and the markers indicated in the graphs. Gray lines represent data from preexposed and vaccinated mice (i.m./i.m.); black lines, data from vaccinated mice that were not preexposed (-/i.m.); and gray areas at bottom of graphs, data for cells isolated from naive animals. Student's t test was performed to compare percentages of difference in median fluorescence intensity for samples derived from 2 individual experiments, of which 1 is displayed here. *P < .05 for comparison between immunized and naive groups; †P < .05 for comparison between immunized groups. CCR5, chemokine (C-C motif) receptor 5.
Figure 3.
Figure 3.
Effect of preexposure on frequencies of Gag-specific CD8+ T cells. Graph shows the kinetics of Gag-specific CD8+ T cell responses in different compartments after vaccination. Mice were preexposed to adenovirus vector of human serotype 5 (AdHu5) and vaccinated with AdHu5gag 3 weeks later (i.m./i.m.) (closed bars); a control group received the vector intramuscularly without preexposure (-/i.m.) (open bars). Frequencies represent ratios of tetramer (Tet)+CD8+ cells to total CD8+ cells (means ± standard deviations from 2 individual experiments). Values obtained from naive animals were subtracted before plotting frequencies for the 2 test groups. Statistical analysis (2-way analysis of variance followed by Bonferroni correction) shows reduction in Gag-specific CD8+ T cell frequencies in mice on preexposure to the vaccine vector in iliac lymph nodes (ILN) (P < .05), spleen, and the genital tract (GT) (P < .01).
Figure 4.
Figure 4.
Effect of immune serum transfer on Gag-specific CD8+ T cell frequencies. Mice were injected intramuscularly twice with AdHu5rab.gp, and serum samples were collected 2 weeks after the boost dose. Pooled immune serum was transferred intraperitoneally into naive mice, followed 1 week later by intramuscular vaccination with AdHu5gag (serum/i.m.). Control groups consisted of animals that received serum from sham-vaccinated mice (-/i.m.) or were preexposed to adenovirus vector of human serotype 5 (AdHu5) before vaccination with AdHu5gag (i.m./i.m.). Frequencies represent ratios of tetramer (Tet)+CD8+ cells to total CD8+ cells (means frequencies ± standard deviations from 2 individual experiments). Values obtained from naive mice tested in parallel were subtracted from frequencies of vaccinated mice before graphs were plotted. Statistical analysis (2-way analysis of variance followed by Bonferroni posttest) shows that frequencies of tetramer+CD8+ cells were significantly lower in the preexposed group than in the serum-transfer group for all compartments analyzed (P < .05). The serum-transfer group had significantly lower frequencies of Gag-specific CD8+ T cells in blood, spleen, and iliac lymph nodes (ILN) (P < .01), but differences in frequencies did not reach statistical significance for cells isolated from the genital tract (GT).
Figure 5.
Figure 5.
Phenotypes of Gag-specific CD8+ T cells. Mice preexposed to adenovirus vector of human serotype 5 (AdHu5) (i.m./i.m.) (gray lines) and nonpreexposed mice (-/i.m.) (black lines) were vaccinated with AdHu5gag. Cells from different compartments were analyzed 1, 6, and 12 weeks after vaccination. Cells were stained with a live cell stain, the Gag-specific tetramer, antibodies to CD8a, and the markers indicated. Graphs show expression of markers on tetramer (Tet)+CD8+ T cells isolated from vaccinated mice. Gray shaded areas show expression of the markers on tetramer −CD8+ T cells from naive mice. Graphs presenting samples from blood and spleens show cells isolated from 5 individual mice, and those from iliac lymph nodes (ILN) show samples pooled from 2 or 3 mice; data from these samples were concatenated using FlowJo software. Graphs of samples derived from the genital tract show results obtained with pooled lymphocytes from 5 mice. Student's t test was used to compare percentage differences in median fluorescence intensity between samples derived from 2 individual experiments, of which 1 is displayed here. *P < .05 for difference between immunized and naive mice; †P < .05 for difference between the 2 immunized groups. CCR5, chemokine (C-C motif) receptor 5.

Similar articles

Cited by

References

    1. Buchbinder SP, Mehrotra DV, Duerr A, et al. Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881–93. - PMC - PubMed
    1. McElrath MJ, De Rosa SC, Moodie Z, et al. Step Study Protocol Team. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008;372:1894–905. - PMC - PubMed
    1. Xiang Z, Li Y, Cun A, et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis. 2006;12:1596–9. - PMC - PubMed
    1. Chen H, Xiang ZQ, Li Y, et al. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol. 2010;84:10522–32. - PMC - PubMed
    1. Fitzgerald JC, Gao GP, Reyes-Sandoval A, et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol. 2003;170:1416–22. - PubMed

Publication types

Substances